Insights provides context and perspective about key pharmacy trends and issues

Expensive Pill Icon
Cost Management
Value-based management seeks go beyond a static, pre-set price tag to uncover true value for drugs and better health for patients. More
Briefing
Expensive Pill
Cost Management
The current model of static, manufacturer-set drug prices is simply unsustainable. Value-based management approaches attempt to incentivize quality and efficacy. More
Briefing
Cost Management
New utilization management criteria ensure appropriate use of PCSK9 inhibitors, which can help lower bad cholesterol levels, but are significantly more expensive first-line therapies More
Briefing
Cost Management
Members may now face higher out-of-pocket costs for their prescriptions, particularly during their deductible phase. Payors can help by applying rebates at point-of-sale. More
Feature
Cost Management
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment and needs... More
Briefing
Cost Management
Limiting pharmaceutical sales activities at academic medical centers can help make a meaningful difference in prescribing patterns, and help reduce drug spend. More
Briefing
Troy Brennan
Cost Management
The current economics of health care are unsustainable and change is critical. More
Video
Pill Bottle with declining chart
Cost Management
Manufacturer-driven brand inflation contributed 8.6 percent to trend, while PBM management solutions, helped reduce it by 7.8 percent. Thirty eight percent of commercial clients having... More
Feature
Cost Management
Pharmaceutical manufacturers’ abuse a provision of the Orphan Drug Act leading to higher prices for drugs for payors and patients More
Feature
Speech bubbles icon
Cost Management
Market and legislative reform can help bend the seemingly relentless upward trajectory of prescription drug price inflation in the U.S. More
Commentary